Arif Khan1, Masood A Khan1, Ahmed N Aljarbou2, Yousef H Aldebasi3, Khaled S Allemailem4, Mohammed A Alsahli1, Shamshir Khan5, Abdulmohsen M Alruwetei4. 1. Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia. 2. Department of Pharmaceutics, College of Pharmacy, Qassim University, Al-Qassim, Buraydah, Saudi Arabia. 3. Department of Optometry, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia. 4. Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia. 5. Dentistry and Pharmacy College, Buraydah Private Colleges, Al-Qassim, Buraydah, Saudi Arabia.
Abstract
PURPOSE: The overexpression of Her-2 in 25-30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated with the anti-Her-2 fab' and encapsulated FASN siRNA against breast cancer cells. METHODS: We evaluated the size, stability, cellular uptake and internalization of various formulations of liposomes. The antiproliferative gene silencing potential was investigated by the cell cytotoxicity, crystal violet, wound healing and Western blot analyses in Her-2+ and Her-2¯ breast cancer cells. RESULTS: The data revealed that both nanosized FASN-siRNA-encapsulated liposomes showed significantly higher cellular uptake and internalization with enhanced stability. The cell viability of Her-2+ SK-BR3 cells treated with the targeted formulation of DSPC/Chol- and DOPE/CHEMS-encapsulating FASN-siRNA reduced to 30% and 20%, respectively, whereas it was found to be 45% and 36% in MCF-7 cells. The wounds were not only failed to close but they became broader in Her-2+ cells treated with targeted liposomes of siRNA. Consequently, the amount of FASN decreased by 80% in SK-BR3 cells treated with non-targeted liposomes and it was 30% and 60% in the MCF-7 cells treated with DSPC/Chol and DOPE/CHEMS liposomes, respectively. CONCLUSION: In this study, we developed the formulation that targeted Her-2 for the suppression of FASN and, therefore, inhibited the proliferation of breast cancer cells.
PURPOSE: The overexpression of Her-2 in 25-30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated with the anti-Her-2 fab' and encapsulated FASN siRNA against breast cancer cells. METHODS: We evaluated the size, stability, cellular uptake and internalization of various formulations of liposomes. The antiproliferative gene silencing potential was investigated by the cell cytotoxicity, crystal violet, wound healing and Western blot analyses in Her-2+ and Her-2¯ breast cancer cells. RESULTS: The data revealed that both nanosized FASN-siRNA-encapsulated liposomes showed significantly higher cellular uptake and internalization with enhanced stability. The cell viability of Her-2+ SK-BR3 cells treated with the targeted formulation of DSPC/Chol- and DOPE/CHEMS-encapsulating FASN-siRNA reduced to 30% and 20%, respectively, whereas it was found to be 45% and 36% in MCF-7 cells. The wounds were not only failed to close but they became broader in Her-2+ cells treated with targeted liposomes of siRNA. Consequently, the amount of FASN decreased by 80% in SK-BR3 cells treated with non-targeted liposomes and it was 30% and 60% in the MCF-7 cells treated with DSPC/Chol and DOPE/CHEMS liposomes, respectively. CONCLUSION: In this study, we developed the formulation that targeted Her-2 for the suppression of FASN and, therefore, inhibited the proliferation of breast cancer cells.
Authors: A S Nosova; O O Koloskova; A A Nikonova; V A Simonova; V V Smirnov; D Kudlay; M R Khaitov Journal: Medchemcomm Date: 2019-02-12 Impact factor: 3.597
Authors: Hao Yin; Rosemary L Kanasty; Ahmed A Eltoukhy; Arturo J Vegas; J Robert Dorkin; Daniel G Anderson Journal: Nat Rev Genet Date: 2014-07-15 Impact factor: 53.242
Authors: Gerben A Koning; Henriëtte W M Morselt; Arko Gorter; Theresa M Allen; Samuel Zalipsky; Gerrit L Scherphof; Jan A A M Kamps Journal: Pharm Res Date: 2003-08 Impact factor: 4.200
Authors: Amit C Nathwani; Ulreke M Reiss; Edward G D Tuddenham; Cecilia Rosales; Pratima Chowdary; Jenny McIntosh; Marco Della Peruta; Elsa Lheriteau; Nishal Patel; Deepak Raj; Anne Riddell; Jun Pie; Savita Rangarajan; David Bevan; Michael Recht; Yu-Min Shen; Kathleen G Halka; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; James Allay; Mark A Kay; Catherine Y C Ng; Junfang Zhou; Maria Cancio; Christopher L Morton; John T Gray; Deokumar Srivastava; Arthur W Nienhuis; Andrew M Davidoff Journal: N Engl J Med Date: 2014-11-20 Impact factor: 176.079
Authors: Arif Khan; Mohammed A Alsahli; Mohammad A Aljasir; Hamzah Maswadeh; Mugahid A Mobark; Faizul Azam; Khaled S Allemailem; Faris Alrumaihi; Fahad A Alhumaydhi; Ahmad A Almatroudi; Naif AlSuhaymi; Masood A Khan Journal: J Inflamm Res Date: 2022-04-08
Authors: Faris Alrumaihi; Masood Alam Khan; Ali Yousif Babiker; Mohammed Alsaweed; Faizul Azam; Khaled S Allemailem; Ahmad A Almatroudi; Syed Rizwan Ahamad; Naif AlSuhaymi; Mahdi H Alsugoor; Ahmed N Algefary; Arif Khan Journal: Pharmaceutics Date: 2022-01-20 Impact factor: 6.321
Authors: Masood Alam Khan; Arif Khan; Mohd Azam; Khaled S Allemailem; Faris Alrumaihi; Ahmad Almatroudi; Fahad A Alhumaydhi; Faizul Azam; Shaheer Hasan Khan; Syeda Fauzia Farheen Zofair; Sumbul Ahmad; Hina Younus Journal: Pharmaceutics Date: 2021-06-15 Impact factor: 6.321
Authors: Arif Khan; Mohammed A Alsahli; Mohammad A Aljasir; Hamzah Maswadeh; Mugahid A Mobark; Faizul Azam; Khaled S Allemailem; Faris Alrumaihi; Fahad A Alhumaydhi; Ameen S S Alwashmi; Ahmed A Almatroudi; Mahdi H Alsugoor; Masood A Khan Journal: Pharmaceutics Date: 2022-01-09 Impact factor: 6.321